Allergy Thera. Regulatory News (AGY)

4 May 2006 12:06

Allergy Therapeutics PLC04 May 2006 Allergy Therapeutics plc, "Allergy Therapeutics" or "the Company" Result of Extraordinary General Meeting Allergy Therapeutics plc (AIM: AGY), the specialiast pharmaceutical companyfocused on allergy vaccination, is pleased to announce that all resolutions atthe Company's Extraordinary General Meeting, held earlier today, were dulypassed. The Board is pleased to report that 19,000,000 new ordinary shares have beenplaced with existing and new investors raising approximately £18.2 million, netof expenses. This additional capital will primarily fund the completion of theCompany's development pipeline of innovative ultra-short course allergyvaccines, Pollinex Quattro, through to registration. It is anticipated that the new shares will commence trading on 5th May 2006. Thenew shares will rank pari passu with the existing shares. Following admission ofthe new shares the Company will have 81,950,632 ordinary shares in issue. Commenting on the announcement, Keith Carter, Chief Executive of AllergyTherapeutics, said: "We are delighted that our shareholders have overwhelmingly approved thefundraising proposed by the Company. We are very excited about the progress ofthe Company to date and the milestones that have been reached. "The capital raised will help us to complete our Phase III programme forPollinex Quattro and will bring the Company closer to delivering the first andonly simple, four shot allergy vaccine therapy to patients worldwide." -ends- For further information please contact: Allergy Therapeutics plc 01903 845 820Keith Carter, Chief ExecutiveIan Postlethwaite, Finance Director Bell Pottinger 020 7861 3863Dan de Belder / Emma Charlton About Allergy Therapeutics plc Allergy Therapeutics plc is a London Stock Exchange (AIM: AGY) listed specialistpharmaceutical company focused on allergy vaccination. It has a profitable corebusiness achieving sales of allergy vaccines of over £22 million through its ownEU sales and marketing infrastructure. Pollinex Quattro incorporates the innovative TLR4 agonist MPL, which acts as anefficient vaccine adjuvant. Allergy Therapeutics has certain exclusiveintellectual property rights to the use of MPL(R) in both injected and oralvaccines. Allergy Therapeutics manufactures its own vaccine products in a MHRA approved,sterile manufacturing facility in Worthing, United Kingdom. In January 2006 theCompany successfully underwent an audit by the MHRA. Placing Statistics Placing Price 100 pence Number of Placing Shares being placed on behalf of the Company 19,000,000 Number of Ordinary Shares in issue following Admission 81,950,632 Percentage of enlarged issued share capital subject to the Placing 23.2% Proceeds of the Placing available to the Company (net of expenses) £18.2 million This information is provided by RNS The company news service from the London Stock Exchange